PDCD1 and colorectal carcinoma: Further, based on preclinical data, co-blockade of TIM3 and PD1 has shown efficacy for solid tumors, leading to the clinical investigation of anti-TIM3 combined with anti-PD1 in the treatment of various malignancies, including CRC [44, 59–61].